As we begin a new year, I want to wish all of you a happy and healthy 2018. I hope the holiday season was magical for you and that the year is off to a great start. Each new year, I like to reflect on the time…
The Gift of Writing for ‘Pulmonary Fibrosis News’
Owlstone Medical is among nine finalists of the IPF Catalyst Challenge to receive $1 million to fund research into idiopathic pulmonary fibrosis (IPF). If it wins, the British company will use the money to promote research into identifying IPF-linked biomarkers in patients’ breath via its proprietary Breath…
Interim results of a Phase 2 clinical trial found an investigative antibody, tralokinumab, failed to demonstrate potential to improve the respiratory function of patients with idiopathic pulmonary fibrosis (IPF). Based on this final, the study has been closed. This and additional safety data were reported in the study “…
It is safe to say that 2017 just wasn’t my year. It also seems that I can find solitude in saying that it wasn’t a great year in general, based on conversations with others. The hardest part of this year for me was the rapid progression of my…
NuMedii is advancing the field of personalized medicine for idiopathic pulmonary fibrosis (IPF) by creating a new advisory board that includes some of the world’s leading specialists in interstitial lung disease to guide a new approach to drug discovery based on artificial intelligence (AI). The California-based company has…
If you’re an individual living with a lung disease, you’re likely very aware of how the weather can impact your ability to breathe. Typically, patients living with idiopathic pulmonary fibrosis (IPF) are impacted by extreme temperatures that often make it difficult to breathe. In the summer months, extreme heat can…
https://www.youtube.com/watch?v=SYssJOKfZ_U Being diagnosed with pulmonary fibrosis can be terrifying and confusing and often takes a long time to come to terms with. In this video from EmpowHER, pulmonary fibrosis patient Dyane talks about what she most fears about the disease and how PF has impacted her life. MORE:…
Bellerophon Therapeutics has enrolled the first pulmonary hypertension patient in a Phase 2b clinical trial of its INOpulse nitric oxide delivery system. The trial (NCT03267108) of the blood-vessel-widening device will cover people with pulmonary hypertension associated with interstitial lung disease, or PH-ILD. This includes people with idiopathic pulmonary fibrosis,…
I feel hopeful and am looking forward to completing meaningful goals I’ve set for 2018. I’ve had times in the past when the idea of setting goals seemed ridiculous because of having such a serious condition. I realized that for me, this was part of grieving all that…
There’s a lot of literature out there that highlights strategies and tips for coping with a life-threatening illness diagnosis. The challenge is that most of this literature is written based on various theories from professionals including psychologists, chronic-illness specialists and doctors. This literature is very rarely written from a patient’s…
